Stock listing
KRX:298380 ABL Bio, Inc. (에이비엘바이오) 주가
Follow ABL Bio, Inc. into a list and get an email when it puts out news.
Share price · KRX:298380
₩35,250 KRW -750 (-2.1%)
Close on Nov 20, 2026
- Day range
- ₩34,900 – ₩37,200 KRWNov 20, 2026
- Volume
- 263,294 sharesNov 20, 2026
- Market cap
- ₩1.97T KRWAt the close on Nov 20, 2026 · price × 55.99M shares outstanding
- 52-week range
- ₩33,900 – ₩257,500 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩16.73B KRWMedian day 278,773 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:298380 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩35,250 | -750 | -2.1% | ₩36,500 | ₩37,200 | ₩34,900 | 263,294 | |
| ₩36,000 | -1,850 | -4.9% | ₩38,050 | ₩38,750 | ₩35,750 | 353,782 | |
| ₩37,850 | -550 | -1.4% | ₩37,600 | ₩39,850 | ₩37,300 | 257,135 | |
| ₩38,400 | -2,250 | -5.5% | ₩41,300 | ₩42,100 | ₩37,950 | 295,559 | |
| ₩40,650 | 0 | 0.0% | ₩41,100 | ₩44,500 | ₩40,300 | 278,951 | |
| ₩40,650 | -1,850 | -4.4% | ₩41,900 | ₩43,650 | ₩39,900 | 440,663 | |
| ₩42,500 | +5,050 | +13.5% | ₩37,200 | ₩42,850 | ₩37,200 | 702,129 | |
| ₩37,450 | +1,850 | +5.2% | ₩36,750 | ₩38,100 | ₩36,050 | 196,067 | |
| ₩35,600 | -450 | -1.2% | ₩35,900 | ₩37,400 | ₩33,900 | 278,595 | |
| ₩36,050 | -3,450 | -8.7% | ₩35,700 | ₩37,500 | ₩35,000 | 470,710 | |
| ₩39,500 | +1,050 | +2.7% | ₩39,750 | ₩43,950 | ₩38,850 | 591,496 | |
| ₩38,450 | +150 | +0.4% | ₩38,350 | ₩38,500 | ₩35,650 | 376,273 | |
| ₩38,300 | -1,450 | -3.6% | ₩39,000 | ₩39,550 | ₩38,000 | 202,887 | |
| ₩39,750 | +550 | +1.4% | ₩38,900 | ₩40,350 | ₩38,600 | 211,198 | |
| ₩39,200 | -1,800 | -4.4% | ₩40,300 | ₩40,800 | ₩38,250 | 265,908 | |
| ₩41,000 | -800 | -1.9% | ₩42,050 | ₩42,450 | ₩40,250 | 251,109 | |
| ₩41,800 | +950 | +2.3% | ₩40,900 | ₩42,800 | ₩40,900 | 292,476 | |
| ₩40,850 | +50 | +0.1% | ₩41,000 | ₩42,600 | ₩40,450 | 234,136 | |
| ₩40,800 | -3,450 | -7.8% | ₩42,800 | ₩43,500 | ₩40,750 | 206,594 | |
| ₩44,250 | -250 | -0.6% | ₩44,050 | ₩44,600 | ₩42,750 | 196,579 | |
| ₩44,500 | -2,250 | -4.8% | ₩46,500 | ₩46,750 | ₩44,200 | 193,055 | |
| ₩46,750 | +2,050 | +4.6% | ₩45,700 | ₩47,400 | ₩45,250 | 219,041 | |
| ₩44,700 | -1,950 | -4.2% | ₩45,650 | ₩46,400 | ₩43,700 | 198,179 | |
| ₩46,650 | +3,300 | +7.6% | ₩42,950 | ₩47,600 | ₩42,300 | 496,603 | |
| ₩43,350 | +2,800 | +6.9% | ₩40,950 | ₩44,800 | ₩40,950 | 386,501 | |
| ₩40,550 | -2,550 | -5.9% | ₩41,200 | ₩41,850 | ₩39,700 | 419,454 | |
| ₩43,100 | -400 | -0.9% | ₩43,100 | ₩44,400 | ₩42,450 | 244,758 | |
| ₩43,500 | -2,100 | -4.6% | ₩43,900 | ₩44,000 | ₩41,700 | 405,165 | |
| ₩45,600 | -2,400 | -5.0% | ₩47,700 | ₩48,450 | ₩45,350 | 302,528 | |
| ₩48,000 | -3,100 | -6.1% | ₩50,100 | ₩50,300 | ₩47,650 | 407,458 | |
| ₩51,100 | -1,400 | -2.7% | ₩53,700 | ₩54,200 | ₩51,100 | 285,829 | |
| ₩52,500 | +1,100 | +2.1% | ₩51,900 | ₩54,100 | ₩51,100 | 310,705 | |
| ₩51,400 | -2,200 | -4.1% | ₩53,600 | ₩54,700 | ₩50,000 | 266,151 | |
| ₩53,600 | +5,100 | +10.5% | ₩48,300 | ₩53,700 | ₩47,350 | 551,114 | |
| ₩48,500 | -800 | -1.6% | ₩49,050 | ₩50,200 | ₩48,250 | 270,560 | |
| ₩49,300 | -900 | -1.8% | ₩49,400 | ₩49,450 | ₩48,050 | 380,995 | |
| ₩50,200 | -600 | -1.2% | ₩51,900 | ₩52,100 | ₩49,750 | 353,309 | |
| ₩50,800 | -300 | -0.6% | ₩49,700 | ₩51,700 | ₩49,350 | 482,461 | |
| ₩51,100 | -2,800 | -5.2% | ₩53,300 | ₩53,400 | ₩50,800 | 457,081 | |
| ₩53,900 | -2,100 | -3.8% | ₩55,300 | ₩55,600 | ₩53,300 | 560,567 | |
| ₩56,000 | -2,100 | -3.6% | ₩57,700 | ₩57,900 | ₩55,600 | 429,127 | |
| ₩58,100 | +200 | +0.3% | ₩57,900 | ₩59,200 | ₩57,300 | 241,907 | |
| ₩57,900 | -1,400 | -2.4% | ₩56,600 | ₩58,300 | ₩54,100 | 829,910 | |
| ₩59,300 | -5,600 | -8.6% | ₩65,000 | ₩67,300 | ₩57,750 | 944,589 | |
| ₩64,900 | -1,200 | -1.8% | ₩65,300 | ₩66,300 | ₩62,700 | 152,510 | |
| ₩66,100 | -1,700 | -2.5% | ₩65,500 | ₩66,800 | ₩65,400 | 118,159 | |
| ₩67,800 | -1,200 | -1.7% | ₩67,600 | ₩68,600 | ₩65,500 | 296,833 | |
| ₩69,000 | +800 | +1.2% | ₩67,700 | ₩69,500 | ₩67,700 | 168,369 | |
| ₩68,200 | -2,900 | -4.1% | ₩70,900 | ₩71,400 | ₩68,100 | 192,626 | |
| ₩71,100 | -300 | -0.4% | ₩71,500 | ₩72,100 | ₩70,500 | 147,749 | |
| ₩71,400 | +3,800 | +5.6% | ₩68,500 | ₩71,900 | ₩68,400 | 169,255 | |
| ₩67,600 | -1,700 | -2.5% | ₩70,300 | ₩71,400 | ₩66,900 | 244,594 | |
| ₩69,300 | -1,700 | -2.4% | ₩69,000 | ₩72,200 | ₩67,600 | 258,963 | |
| ₩71,000 | -1,700 | -2.3% | ₩72,100 | ₩72,900 | ₩70,500 | 173,680 | |
| ₩72,700 | -4,200 | -5.5% | ₩74,200 | ₩74,300 | ₩70,200 | 328,730 | |
| ₩76,900 | +900 | +1.2% | ₩78,100 | ₩81,300 | ₩75,600 | 367,300 | |
| ₩76,000 | +1,400 | +1.9% | ₩73,500 | ₩77,200 | ₩73,500 | 241,871 | |
| ₩74,600 | 0 | 0.0% | ₩75,400 | ₩76,700 | ₩74,000 | 152,704 | |
| ₩74,600 | -1,200 | -1.6% | ₩74,100 | ₩74,800 | ₩70,500 | 318,732 | |
| ₩75,800 | +600 | +0.8% | ₩75,200 | ₩77,500 | ₩74,200 | 202,899 | |
| ₩75,200 | -7,300 | -8.8% | ₩79,800 | ₩80,000 | ₩74,600 | 286,381 | |
| ₩82,500 | +2,800 | +3.5% | ₩83,900 | ₩85,000 | ₩79,300 | 272,917 |
- Ticker
- KRX:298380
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Mar 30, 2026
Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Latest news
Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Mar 30, 2026
Closed ₩165,900 (-3.3%) on Mar 31, 2026
ABL Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Mar 30, 2026 · oldest 2026
Valuation
EV/sales 52.7× against a median of 14.5×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩1.81T KRW
- P/E
- Loss
- EV/sales
- 52.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 11.5×
- Gross margin
- 100.0%
- Operating margin
- −250.9%
- Net margin
- −229.4%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ABL Bio, Inc. · KRX:298380 | US$1.48B | US$1.35B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.40B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.43B | US$1.15B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| Median of the others | US$1.44B | US$1.27B | 14.5× | 31.4× | 2.4× | −121.0% | 0.1× | 1.49 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 270000.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- -59.00 · 2 analysts
- Revenue, year to Dec 2026
- 89B · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Sang Hoon Lee | President (CEO) |
| Jaecheon Jerry Lee | Chief Financial Officer |
| Hakju Kwon | Senior Vice President, Head of Neuroscience & NCD |
| Eunkyung Kim | Chief Medical & Clinical Development Officer |
| Jaeho Jung | Chief of Discovery |
| Jungdae Kim | Chief Operations Officer |
| Sung-Ju Moon | Chief Technology Officer |
| Weon Kyoo You | Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 11, 2026 · Before open | −1.8% |
| Q3 2025 | Nov 10, 2025 · Before open | −0.8% |
| Q2 2025 | Aug 11, 2025 · Before open | +4.0% |
| Q1 2025 | May 13, 2025 · Before open | +3.4% |
| Q4 2024 | Feb 13, 2025 · Before open | −4.9% |
| Q3 2024 | Nov 8, 2024 · After close | +7.8% |
| Q2 2024 | Aug 9, 2024 · After close | +3.9% |
| Q1 2024 | May 14, 2024 · After close | +2.3% |
| Q4 2023 | Mar 29, 2024 · Before open | +8.2% |
| Q3 2023 | Nov 10, 2023 · After close | −2.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 11, 2023 · After close | −3.1% |
| Q1 2023 | May 15, 2023 · After close | −1.3% |
| Q4 2022 | Feb 10, 2023 · After close | +0.2% |
| Q3 2022 | Nov 14, 2022 · After close | +9.6% |
| Q2 2022 | Aug 12, 2022 · Before open | −3.7% |
| Q1 2022 | May 16, 2022 · Before open | +1.4% |
| Q4 2021 | Feb 11, 2022 · Before open | −8.1% |
| Q3 2021 | Nov 12, 2021 | +3.0% |
| Quarter to Jun 30, 2021 | Aug 12, 2021 | −5.8% |
| Quarter to Mar 31, 2021 | May 14, 2021 | +4.1% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79.3B | 33.4B | 65.5B | 67.3B | 5.33B | 8.10B | 3.99B | 1.26B | 71.4M | 0 |
| Cost of revenue | 105.2M | 67.3M | ||||||||
| Gross profit | 79.3B | 33.4B | 65.5B | 67.3B | 5.33B | 8.10B | 3.96B | 1.15B | 4.11M | |
| Research and development | 93.0B | 74.1B | 52.0B | 48.4B | 41.0B | 52.8B | 39.6B | 18.1B | 6.67B | |
| Selling, general and administrative | 14.5B | 13.7B | 10.9B | 8.85B | 12.8B | 11.3B | 10.1B | 5.98B | 2.34B | 1.09B |
| Operating income | -40.3B | -59.4B | -2.62B | 906.5M | -52.3B | -59.6B | -40.4B | -24.0B | -9.65B | -3.52B |
| Depreciation and amortization | 3.45B | 2.23B | 2.59B | 2.32B | 2.16B | 2.06B | 1.65B | 621.0M | 403.5M | 154.5M |
| EBITDA | -36.8B | -57.1B | -27.3M | 3.23B | -50.1B | -57.6B | -38.8B | -23.4B | -9.25B | -3.36B |
| Interest expense | 993.0M | 36.0M | 2.15B | 1.33B | 42.0M | 72.8M | 95.9M | 0 | 0 | 0 |
| Income before tax | -37.9B | -55.5B | -2.65B | 3.21B | -43.6B | -55.6B | -37.0B | -117.2B | -74.7B | -13.7B |
| Net income | -37.8B | -55.5B | -2.65B | 3.21B | -43.6B | -55.6B | -37.0B | -117.2B | -74.7B | -13.7B |
| Earnings per share, basic | -685.83 | -1,150.11 | -55.26 | 67.33 | -924.34 | -1,202.39 | -816.82 | -2,629.33 | -3,874.39 | -709.45 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 112.0B | 56.3B | 28.1B | 25.1B | 21.6B | 40.7B | 91.1B | 122.0B | 2.00B | 5.34B |
| Short-term investments | 2.96B | 84.4B | 43.1B | 53.2B | 22.1B | 29.7B | 42.1B | 17.9B | 7.17B | |
| Receivables | 59.1B | 616.7M | 50.9M | 451.8M | 83.9M | 1.19B | 442.2M | 5.70B | ||
| Current assets | 176.1B | 144.2B | 75.5B | 80.5B | 45.5B | 71.9B | 134.7B | 161.1B | 9.44B | 5.69B |
| Property, plant and equipment | 85.4B | 76.0B | 6.71B | 3.30B | 4.07B | 5.04B | 2.70B | 1.92B | 1.48B | |
| Total assets | 280.9B | 232.0B | 160.1B | 185.2B | 65.5B | 99.9B | 142.9B | 168.9B | 20.4B | 7.53B |
| Current liabilities | 123.5B | 63.4B | 41.8B | 72.2B | 8.75B | 7.97B | 9.33B | 11.6B | 1.34B | 303.0M |
| Long-term debt | 0 | 43.0B | 40.0B | 0 | 7.63B | 2.33B | ||||
| Total debt | 555.3M | 1.08B | 7.63B | 2.33B | ||||||
| Total liabilities | 124.2B | 64.7B | 86.1B | 115.7B | 9.50B | 9.23B | 10.9B | 11.9B | 106.3B | 19.6B |
| Shareholders' equity | 154.7B | 167.3B | 74.1B | 69.5B | 56.0B | 90.7B | 132.0B | 157.0B | -86.0B | -12.1B |
| Shares outstanding | 55.1M | 48.3M | 47.9M | 47.7M | 47.1M | 46.2M | 45.3M | 44.6M | 19.3M | 19.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.3B | -69.4B | -28.4B | 72.1B | -40.6B | -47.3B | -23.9B | -12.7B | -7.14B | -3.12B |
| Capital spending | -20.7B | -9.06B | -5.84B | -2.06B | -1.24B | -434.7M | -1.59B | -1.15B | -802.5M | -2.13B |
| Free cash flow | -61.9B | -78.5B | -34.2B | 68.5B | -41.9B | -47.9B | -25.4B | -13.8B | -7.95B | -5.24B |
| Cash from investing | -47.2B | 29.9B | -71.2B | 20.2B | -3.63B | -8.26B | -22.8B | -16.2B | -2.13B | |
| Cash from financing | 144.6B | 1.44B | 4.65B | 284.1M | 598.3M | -47.5M | 155.6B | 20.0B | 10.6B | |
| Share buybacks | 145.9B | 1.72B | 5.75B | 1.26B | 1.50B | 651.9M | 160.0B | 4.01B | 3.56B | |
| Change in cash | 55.7B | 28.2B | 2.93B | 3.55B | -19.1B | -50.5B | -30.9B | 120.0B | -3.34B | 5.34B |
Cap table
Built by 6ix from ABL Bio, Inc.’s releases
- Common shares
- 55,987,463
- Fully diluted
- 55,987,463
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 55,987,463 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 55,987,463 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eunkyung Kim | Chief Medical & Clinical Development Officer · Since at least Nov 5, 2026 |
| Hakju Kwon | Senior Vice President, Head of Neuroscience & NCD · Since at least Nov 5, 2026 |
| Jaecheon Jerry Lee | Chief Financial Officer · Since at least Nov 5, 2026 |
| Jaeho Jung | Chief of Discovery · Since at least Nov 5, 2026 |
| Jungdae Kim | Chief Operations Officer · Since at least Nov 5, 2026 |
| Sang Hoon Lee | President (CEO) · Since at least Nov 5, 2026 |
| Sung-Ju Moon | Chief Technology Officer · Since at least Nov 5, 2026 |
| Weon Kyoo You | Chief Scientific Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about ABL Bio, Inc.